Terminated EARLY_PHASE1 INTERVENTIONAL NCT01015300

Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease

D0904 - A Pilot Study of Bevacizumab (Avastin) in Patients With Unresectable or Recurrent Hemangioblastoma From Von Hippel-Lindau Disease.

Sponsor: Dartmouth-Hitchcock Medical Center

Conditions Hemangioblastomas Von Hippel Lindau Disease

Interventions Avastin

Updated 6 times since 2017 Last updated: May 9, 2012 Started: Dec 31, 2009 Primary completion: Oct 31, 2011 Completion: Apr 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study terminated due to low accrual.

Other terminated trials from Dartmouth-Hitchcock Medical Center

See all terminations from Dartmouth-Hitchcock Medical Center

A EARLY_PHASE1 clinical study on Hemangioblastomas and Von Hippel Lindau Disease, this trial is terminated or withdrawn. The trial is conducted by Dartmouth-Hitchcock Medical Center and has accumulated 6 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated EARLY_PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated EARLY_PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated EARLY_PHASE1
Feb 2017 — Jun 2018 [monthly]

Terminated EARLY_PHASE1

Phase: Phase 0 → EARLY_PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated Phase 0

First recorded

Dec 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dartmouth-Hitchcock Medical Center
Genentech, Inc.

Data source: Dartmouth-Hitchcock Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lebanon, United States